CD79B Y196 mutation is a potent predictive marker for favorable response to R‐MPV in primary central nervous system lymphoma

CD79B Y196 mutation is a potent predictive marker for favorable response to R‐MPV in primary central nervous system lymphoma

Abstract Background Rituximab, high‐dose methotrexate (HD‐MTX), procarbazine and vincristine (R‐MPV), has significantly prolonged the survival of patients with primary central nervous system lymphoma (PCNSL), but predictive factors for response to R‐MPV have not yet been investigated. Herein, we inv...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй
Үндсэн зохиолчид: Junya Yamaguchi, Fumiharu Ohka, Chalise Lushun, Kazuya Motomura, Kosuke Aoki, Kazuhito Takeuchi, Yuichi Nagata, Satoshi Ito, Nobuhiko Mizutani, Masasuke Ohno, Noriyuki Suzaki, Syuntaro Takasu, Yukio Seki, Takahisa Kano, Kenichi Wakabayashi, Hirofumi Oyama, Shingo Kurahashi, Kuniaki Tanahashi, Masaki Hirano, Hiroyuki Shimizu, Yotaro Kitano, Sachi Maeda, Shintaro Yamazaki, Toshihiko Wakabayashi, Yutaka Kondo, Atsushi Natsume, Ryuta Saito
Формат: Өгүүллэг
Хэл сонгох:English
Хэвлэсэн: Wiley 2023-03-01
Цуврал:Cancer Medicine
Нөхцлүүд:
CD79B
MYD88
primary central nervous system lymphoma
rapid molecular diagnosis
R‐MPV
Онлайн хандалт:https://doi.org/10.1002/cam4.5512

Интернэт

https://doi.org/10.1002/cam4.5512

Ижил төстэй зүйлс